Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in Ningbo, has announced the successful completion of patient enrollment in a confirmatory study for its flagship product, the JensClip transcatheter mitral valve repair and clamping system. The system is designed to address severe mitral regurgitation, a condition that affects the proper functioning of the mitral valve within the heart. The company has also reported the conclusion of one-month clinical follow-ups, which have yielded excellent clinical outcomes.
The JensClip system stands out for its innovative locking mechanism, featuring claw walls that can grip the leaflets of the mitral valve from multiple sides, effectively reducing the backflow of blood known as reflux. Its conveying system design provides physicians with the flexibility to manipulate the instrument in a full 360 degrees and in all directions, ensuring ease of use and high maneuverability.- Flcube.com
